Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.

Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike O.

Blood Adv. 2020 Feb 25;4(4):599-606. doi: 10.1182/bloodadvances.2019000795.

PMID:
32074275
2.

A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Kochanny SE, Worden FP, Adkins DR, Lim DW, Bauman JE, Wagner SA, Brisson RJ, Karrison TG, Stadler WM, Vokes EE, Seiwert TY.

Cancer. 2020 Feb 19. doi: 10.1002/cncr.32762. [Epub ahead of print]

PMID:
32073648
3.

Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors.

Schreiber K, Karrison TG, Wolf SP, Kiyotani K, Steiner M, Littmann ER, Pamer EG, Kammertoens T, Schreiber H, Leisegang M.

Cancer Immunol Res. 2020 Feb;8(2):192-202. doi: 10.1158/2326-6066.CIR-19-0567. Epub 2019 Dec 12.

PMID:
31831634
4.

Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing.

Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite BN, Kindler HL, Sharma MR.

Clin Cancer Res. 2020 Jan 1;26(1):18-24. doi: 10.1158/1078-0432.CCR-19-1483. Epub 2019 Sep 26.

PMID:
31558477
5.

Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.

Ramírez J, House LK, Karrison TG, Janisch LA, Turcich M, Salgia R, Ratain MJ, Sharma MR.

J Clin Pharmacol. 2019 Dec;59(12):1632-1640. doi: 10.1002/jcph.1476. Epub 2019 Jul 5.

PMID:
31274208
6.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE.

Ann Oncol. 2019 Oct 1;30(10):1673. doi: 10.1093/annonc/mdz171. No abstract available.

PMID:
31168601
7.

A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.

Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, Marsh R, Kozloff MF, Polite BN, Catenacci DVT, Kindler HL.

Cancer. 2019 May 15;125(10):1629-1636. doi: 10.1002/cncr.31938. Epub 2019 Jan 15.

PMID:
30645764
8.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE.

Ann Oncol. 2019 Feb 1;30(2):297-302. doi: 10.1093/annonc/mdy522.

9.

Effects of driving distance and transport time on mortality among Level I and II traumas occurring in a metropolitan area.

Karrison TG, Philip Schumm L, Kocherginsky M, Thisted R, Dirschl DR, Rogers S.

J Trauma Acute Care Surg. 2018 Oct;85(4):756-765. doi: 10.1097/TA.0000000000002041.

PMID:
30086071
10.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.

11.

Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.

Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ.

Ann Oncol. 2016 May;27(5):908-13. doi: 10.1093/annonc/mdw051. Epub 2016 Feb 15.

12.

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.

O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML.

Clin Cancer Res. 2015 Nov 15;21(22):5092-9. doi: 10.1158/1078-0432.CCR-15-0427. Epub 2015 Jul 21.

13.

Building firm foundations for therapy development.

Dignam JJ, Karrison TG.

J Natl Cancer Inst. 2015 Feb 20;107(3). pii: djv016. doi: 10.1093/jnci/djv016. Print 2015 Mar. No abstract available.

PMID:
25710961
14.

Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.

Maitland ML, Xu CF, Cheng YC, Kistner-Griffin E, Ryan KA, Karrison TG, Das S, Torgerson D, Gamazon ER, Thomeas V, Levine MR, Wilson PA, Bing N, Liu Y, Cardon LR, Pandite LN, O'Connell JR, Cox NJ, Mitchell BD, Ratain MJ, Shuldiner AR.

Clin Cancer Res. 2015 Jan 15;21(2):365-72. doi: 10.1158/1078-0432.CCR-14-1683. Epub 2014 Nov 19.

15.

Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.

Das LC, Karrison TG, Witt ME, Muller C, Stenson K, Blair EA, Cohen EE, Seiwert TY, Haraf DJ, Vokes EE.

Ann Oncol. 2015 Jan;26(1):198-205. doi: 10.1093/annonc/mdu511. Epub 2014 Oct 30.

16.

Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.

Sharma MR, Gray E, Goldberg RM, Sargent DJ, Karrison TG.

J Clin Oncol. 2015 Jan 1;33(1):36-41. doi: 10.1200/JCO.2014.57.2826. Epub 2014 Oct 27.

17.

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE.

J Clin Oncol. 2014 Sep 1;32(25):2735-43. doi: 10.1200/JCO.2013.54.6309. Epub 2014 Jul 21.

18.

Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.

Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML.

Clin Pharmacol Ther. 2014 Jul;96(1):27-35. doi: 10.1038/clpt.2014.63. Epub 2014 Mar 17.

19.

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.

Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE.

BMC Cancer. 2014 Jan 4;14:5. doi: 10.1186/1471-2407-14-5.

20.

Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors.

Thomeas V, Chow S, Gutierrez JO, Karovic S, Wroblewski K, Kistner-Griffin E, Karrison TG, Maitland ML.

J Clin Pharmacol. 2014 Jun;54(6):682-7. doi: 10.1002/jcph.254. Epub 2014 Jan 17.

21.

Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.

Arina A, Schreiber K, Binder DC, Karrison TG, Liu RB, Schreiber H.

J Immunol. 2014 Feb 1;192(3):1286-93. doi: 10.4049/jimmunol.1202498. Epub 2013 Dec 23.

22.

Validation of a new bowel preparation scale for measuring colon cleansing for colonoscopy: the chicago bowel preparation scale.

Gerard DP, Foster DB, Raiser MW, Holden JL, Karrison TG.

Clin Transl Gastroenterol. 2013 Dec 5;4:e43. doi: 10.1038/ctg.2013.16.

23.

Quantitative allelic test--a fast test for very large association studies.

Lee SM, Karrison TG, Cox NJ, Im HK.

Genet Epidemiol. 2013 Dec;37(8):831-9. doi: 10.1002/gepi.21768. Epub 2013 Nov 1.

24.

Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.

Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE.

Clin Cancer Res. 2013 Jun 1;19(11):3059-67. doi: 10.1158/1078-0432.CCR-12-3829. Epub 2013 Apr 3.

25.

Estimation of renal cell carcinoma treatment effects from disease progression modeling.

Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR.

Clin Pharmacol Ther. 2013 Apr;93(4):345-51. doi: 10.1038/clpt.2012.263. Epub 2012 Dec 27.

26.

Estimation of progression-free survival in the randomized discontinuation trial design.

Karrison TG.

J Clin Oncol. 2013 Feb 20;31(6):814. doi: 10.1200/JCO.2012.46.1087. Epub 2013 Jan 14. No abstract available.

PMID:
23319693
27.

Evidence-based role of bevacizumab in non-small cell lung cancer.

Vokes EE, Salgia R, Karrison TG.

Ann Oncol. 2013 Jan;24(1):6-9. doi: 10.1093/annonc/mds608. No abstract available.

PMID:
23251009
28.

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE.

J Clin Oncol. 2012 Jul 10;30(20):2509-15. doi: 10.1200/JCO.2011.41.5869. Epub 2012 Jun 4.

29.

Spleen cells from young but not old immunized mice eradicate large established cancers.

Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A, Karrison TG, Weichselbaum RR, Rowley DA, Schreiber H.

Clin Cancer Res. 2012 May 1;18(9):2526-33. doi: 10.1158/1078-0432.CCR-12-0127. Epub 2012 Mar 13.

30.

Resampling phase III data to assess phase II trial designs and endpoints.

Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJ.

Clin Cancer Res. 2012 Apr 15;18(8):2309-15. doi: 10.1158/1078-0432.CCR-11-1815. Epub 2012 Jan 27.

31.
32.

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.

Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, Villaflor V, Hensing TA, Krausz T, Vokes EE, Husain AN, Ferguson MK, Karrison TG, Salgia R.

J Clin Bioinforma. 2011 Feb 28;1(8):1-11. doi: 10.1186/2043-9113-1-8.

33.

Outcomes in black patients with early breast cancer treated with breast conservation therapy.

Nichols MA, Mell LK, Hasselle MD, Karrison TG, MacDermed D, Meriwether A, Witt ME, Weichselbaum RR, Chmura SJ.

Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):392-9. doi: 10.1016/j.ijrobp.2009.11.017. Epub 2010 Apr 29.

PMID:
20434849
34.

Phase II study of sunitinib malate in head and neck squamous cell carcinoma.

Choong NW, Kozloff M, Taber D, Hu HS, Wade J 3rd, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EE.

Invest New Drugs. 2010 Oct;28(5):677-83. doi: 10.1007/s10637-009-9296-7. Epub 2009 Aug 4.

PMID:
19649772
35.

Frequency of failure to inform patients of clinically significant outpatient test results.

Casalino LP, Dunham D, Chin MH, Bielang R, Kistner EO, Karrison TG, Ong MK, Sarkar U, McLaughlin MA, Meltzer DO.

Arch Intern Med. 2009 Jun 22;169(12):1123-9. doi: 10.1001/archinternmed.2009.130. Erratum in: Arch Intern Med. 2009 Sep 28;169(17):1626.

PMID:
19546413
36.

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE.

Lancet Oncol. 2009 Mar;10(3):247-57. doi: 10.1016/S1470-2045(09)70002-6. Epub 2009 Feb 7.

37.

Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock W.

Invest New Drugs. 2008 Jun;26(3):233-9. doi: 10.1007/s10637-008-9115-6. Epub 2008 Jan 24.

38.

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.

Karrison TG, Maitland ML, Stadler WM, Ratain MJ.

J Natl Cancer Inst. 2007 Oct 3;99(19):1455-61. Epub 2007 Sep 25. Erratum in: J Natl Cancer Inst. 2007 Dec 5;99(23):1819.

PMID:
17895472
39.

Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.

Ratain MJ, Karrison TG.

Clin Cancer Res. 2007 Feb 1;13(3):781-2. No abstract available.

40.

Radiographic texture analysis of densitometer-generated calcaneus images differentiates postmenopausal women with and without fractures.

Vokes TJ, Giger ML, Chinander MR, Karrison TG, Favus MJ, Dixon LB.

Osteoporos Int. 2006 Oct;17(10):1472-82. Epub 2006 Jul 13.

PMID:
16838099
41.

A group sequential, response-adaptive design for randomized clinical trials.

Karrison TG, Huo D, Chappell R.

Control Clin Trials. 2003 Oct;24(5):506-22. Review.

PMID:
14500050
42.

The aspect ratio (dome/neck) of ruptured and unruptured aneurysms.

Weir B, Amidei C, Kongable G, Findlay JM, Kassell NF, Kelly J, Dai L, Karrison TG.

J Neurosurg. 2003 Sep;99(3):447-51.

PMID:
12959428
43.

Predictors of emergency medical services utilization by elders.

Shah MN, Glushak C, Karrison TG, Mulliken R, Walter J, Friedmann PD, Hayley DC, Chin MH.

Acad Emerg Med. 2003 Jan;10(1):52-8.

44.

Factors associated with older patients' satisfaction with care in an inner-city emergency department.

Nerney MP, Chin MH, Jin L, Karrison TG, Walter J, Mulliken R, Miller A, Hayley DC, Friedmann PD.

Ann Emerg Med. 2001 Aug;38(2):140-5.

PMID:
11468608
45.

Early revisit, hospitalization, or death among older persons discharged from the ED.

Friedmann PD, Jin L, Karrison TG, Hayley DC, Mulliken R, Walter J, Chin MH.

Am J Emerg Med. 2001 Mar;19(2):125-9.

PMID:
11239256
46.

A benzodiazepine hypnotic facilitates adaptation of circadian rhythms and sleep-wake homeostasis to an eight hour delay shift simulating westward jet lag.

Buxton OM, Copinschi G, Van Onderbergen A, Karrison TG, Van Cauter E.

Sleep. 2000 Nov 1;23(7):915-27.

PMID:
11083601
47.

RESPONSE: re: dormancy of mammary carcinoma after mastectomy

Karrison TG, Ferguson DJ, Meier P.

J Natl Cancer Inst. 2000 Jul 5;92(13):1101A-101. No abstract available.

PMID:
10880559
48.

Quality of diabetes care in community health centers.

Chin MH, Auerbach SB, Cook S, Harrison JF, Koppert J, Jin L, Thiel F, Karrison TG, Harrand AG, Schaefer CT, Takashima HT, Egbert N, Chiu SC, McNabb WL.

Am J Public Health. 2000 Mar;90(3):431-4.

49.

Appropriateness of medication selection for older persons in an urban academic emergency department.

Chin MH, Wang LC, Jin L, Mulliken R, Walter J, Hayley DC, Karrison TG, Nerney MP, Miller A, Friedmann PD.

Acad Emerg Med. 1999 Dec;6(12):1232-42.

50.

Older patients' health-related quality of life around an episode of emergency illness.

Chin MH, Jin L, Karrison TG, Mulliken R, Hayley DC, Walter J, Miller A, Friedmann PD.

Ann Emerg Med. 1999 Nov;34(5):595-603.

PMID:
10533006

Supplemental Content

Loading ...
Support Center